Jonathan L Halperin

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. doi request reprint Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?
    Jonathan L Halperin
    The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    Mt Sinai J Med 79:705-20. 2012
  2. ncbi request reprint Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options
    Christopher J Varughese
    The Cardiovascular Institute, Mount Sinai Medical Center, Box 1030, Fifth Avenue at 100th Street, New York, NY 10029 6574, USA
    J Interv Card Electrophysiol 35:19-27. 2012
  3. doi request reprint Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation
    Jeremy P Berman
    Division of Hospital Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Hosp Pract (1995) 41:37-48. 2013
  4. pmc Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Box 1497, Mount Sinai School of Medicine, 1428 Madison Avenue, New York, NY 10029, USA
    Pharmacogenomics 13:297-307. 2012
  5. ncbi request reprint Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects
    Daniella L Kadian-Dodov
    Vascular Medicine Section, The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Vasc Med 18:290-7. 2013
  6. ncbi request reprint Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, 1 Gustave L Levy Place, New York, NY 10029 6574, USA
    Expert Rev Cardiovasc Ther 2:163-74. 2004
  7. doi request reprint Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial
    Vivek Y Reddy
    Helmsley Electrophysiology Center, The Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1030, New York, NY 10029, USA
    Circulation 127:720-9. 2013
  8. ncbi request reprint Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation
    Jonathan L Halperin
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Am Coll Cardiol 45:1-9. 2005
  9. ncbi request reprint Anticoagulation for atrial fibrillation in the elderly
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, The Marie Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, Fifth Avenue at 100th Street, New York, NY 10029, USA
    Am J Geriatr Cardiol 14:81-6. 2005
  10. doi request reprint Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit
    Sandeep R Gangireddy
    Helmsley Electrophysiology Center, Mount Sinai School of Medicine, New York City, NY, USA
    Eur Heart J 33:2700-8. 2012

Collaborators

Detail Information

Publications26

  1. doi request reprint Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?
    Jonathan L Halperin
    The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    Mt Sinai J Med 79:705-20. 2012
    ..However, important questions about patient management with these new agents have not been fully answered by studies completed to date and clinical inertia must yet be overcome...
  2. ncbi request reprint Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options
    Christopher J Varughese
    The Cardiovascular Institute, Mount Sinai Medical Center, Box 1030, Fifth Avenue at 100th Street, New York, NY 10029 6574, USA
    J Interv Card Electrophysiol 35:19-27. 2012
    ..This review provides an update on recent advancements in antithrombotic therapy for stroke prevention in patients with AF...
  3. doi request reprint Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation
    Jeremy P Berman
    Division of Hospital Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Hosp Pract (1995) 41:37-48. 2013
    ..In this article, we provide an overview of the 3 novel oral anticoagulants for treating patients with AF and discuss the latest findings from subgroup analyses...
  4. pmc Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Box 1497, Mount Sinai School of Medicine, 1428 Madison Avenue, New York, NY 10029, USA
    Pharmacogenomics 13:297-307. 2012
    ....
  5. ncbi request reprint Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects
    Daniella L Kadian-Dodov
    Vascular Medicine Section, The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Vasc Med 18:290-7. 2013
    ..In conclusion, genotype-guided warfarin-dosing algorithms may rely more on genetic variables in healthier individuals than in patients with clinical confounders...
  6. ncbi request reprint Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, 1 Gustave L Levy Place, New York, NY 10029 6574, USA
    Expert Rev Cardiovasc Ther 2:163-74. 2004
    ..The open-label SPORTIF III trial confirmed the noninferiority of ximelagatran versus warfarin. Publication of the full results from SPORTIF V is pending...
  7. doi request reprint Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial
    Vivek Y Reddy
    Helmsley Electrophysiology Center, The Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1030, New York, NY 10029, USA
    Circulation 127:720-9. 2013
    ....
  8. ncbi request reprint Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation
    Jonathan L Halperin
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Am Coll Cardiol 45:1-9. 2005
    ..In terms of preventing thromboembolism without hemorrhage, ximelagatran may have a more favorable benefit:risk profile than warfarin for patients with AF...
  9. ncbi request reprint Anticoagulation for atrial fibrillation in the elderly
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, The Marie Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, Fifth Avenue at 100th Street, New York, NY 10029, USA
    Am J Geriatr Cardiol 14:81-6. 2005
    ..Other antithrombotic agents are under development as alternatives to warfarin, but sufficient data are not yet available to justify their clinical use in patients with atrial fibrillation...
  10. doi request reprint Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit
    Sandeep R Gangireddy
    Helmsley Electrophysiology Center, Mount Sinai School of Medicine, New York City, NY, USA
    Eur Heart J 33:2700-8. 2012
    ..We aim to estimate the net clinical benefit (NCB) of percutaneous LAA closure...
  11. doi request reprint What can ongoing clinical trials of anticoagulants demonstrate?
    Jonathan L Halperin
    Mount Sinai Medical Center, New York, New York 10029 6574, USA jonathan
    J Cardiovasc Med (Hagerstown) 10:610-5. 2009
    ..Evidence-based data from trials such as these will pave the way for new anticoagulants, with the goal of bringing optimum prophylactic therapy to those requiring anticoagulation...
  12. doi request reprint Stroke prevention in the high-risk atrial fibrillation patient: Medical management
    Michael Broukhim
    The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029, USA
    Curr Cardiol Rep 13:9-17. 2011
    ....
  13. pmc Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study
    Usman Baber
    Zena and Michael A Wiener Cardiovascular Institute and Marie Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY, USA
    Circ Arrhythm Electrophysiol 4:26-32. 2011
    ..73 to 7.15) among those with stage 1 to 2, stage 3, and stage 4 to 5 CKD. The association between CKD and prevalent AF remained statistically significant after further multivariable adjustment and was consistent across numerous subgroups...
  14. ncbi request reprint New anticoagulants for prevention of stroke in patients with atrial fibrillation
    Juan F Viles-Gonzalez
    Cardiovascular Institute, Mount Sinai Medical Center, New York, New York, USA
    J Cardiovasc Electrophysiol 22:948-55. 2011
    ..This review focuses on advances in the development of novel antithrombotic agents to provide practical information to clinicians on the use of these new drugs in patients with AF...
  15. doi request reprint Antithrombotic therapy for patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention: a review
    Andrew Krasner
    The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    Curr Cardiol Rep 15:378. 2013
    ....
  16. pmc CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, NY 10029, USA
    Pharmacogenomics 10:1243-55. 2009
    ..1173C>T) commonly found among Caucasians. Therefore, this study sought to identify other CYP2C9 and VKORC1 alleles important in warfarin dose variability and to determine their frequencies in different racial and ethnic groups...
  17. ncbi request reprint Novel antiplatelet and anticoagulant agents in the cardiac care unit
    Vaani Panse Garg
    Department of Medicine, The Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, Fifth Avenue at 100th Street, New York, NY 10029 6574, USA
    Cardiol Clin 31:533-44, viii. 2013
    ..The clinical use of these drugs in cardiac intensive care is discussed, focusing on the management of acute coronary syndromes, ischemic stroke, atrial fibrillation, and venous thromboembolism. ..
  18. doi request reprint Ineligibility for anticoagulation in patients with atrial fibrillation
    Ian Del Conde
    The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    Am J Med 126:105-11. 2013
    ....
  19. ncbi request reprint Left atrial appendage closure for stroke prevention in atrial fibrillation: state of the art and current challenges
    Tariqshah M Syed
    Department of Cardiology, Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Nat Clin Pract Cardiovasc Med 4:428-35. 2007
    ..Here we discuss the LAA in relation to AF-related embolic stroke, and how LAA occlusion devices could be used in stroke prevention in patients who cannot tolerate chronic anticoagulant therapy...
  20. doi request reprint Recurrent orthostatic global amnesia in a patient with postoperative hyperfibrinogenemia
    Brett A Sealove
    Mount Sinai School of Medicine, New York, New York 10029, USA
    J Stroke Cerebrovasc Dis 17:241-3. 2008
    ..In conclusion, these observations implicate ischemia caused by hemodynamic vascular insufficiency as a possible cause of TGA...
  21. ncbi request reprint Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)
    Jonathan L Halperin
    Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Am Heart J 146:431-8. 2003
    ..0-3.0)...
  22. doi request reprint Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty
    Jeffrey Bander
    Mount Sinai School of Medicine, Zena and Michael A Wiener Cardiovascular Institute, One Gustave L Levy Place, Box 1030, New York, NY 10029, USA
    Thromb Haemost 108:86-93. 2012
    ..These findings suggest that a portion of the haematologic benefit of AVR may be due to a postoperative decline in ADAMTS-13 rather than solely to relief of AS as previously thought...
  23. doi request reprint Rate or rhythm control for atrial fibrillation: update and controversies
    Jason S Chinitz
    Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Am J Med 125:1049-56. 2012
    ..Because safer and more effective pharmacologic and interventional therapies are now available, an individualized approach to atrial fibrillation management is essential...
  24. doi request reprint Aortic regurgitation: disease progression and management
    Seth H Goldbarg
    The Cardiovascular Institute, Box 1030, Mount Sinai Medical Center, One Gustave L Levy Place, New York, NY 10029, USA
    Nat Clin Pract Cardiovasc Med 5:269-79. 2008
    ..In this Review, we examine the epidemiology of AR in terms of the interplay between arterial and ventricular forces marking progression of disease over time, and analyze the practice guidelines regarding diagnosis and treatment...
  25. ncbi request reprint Unstable angina in a patient with anomalous origin of the left main coronary artery from the right sinus of Valsalva
    Biana Trost
    The Zena and Michael A Weiner Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, USA
    Rev Cardiovasc Med 11:112-6. 2010
    ..Diagnosis and management of patients with this coronary anomaly are discussed...
  26. doi request reprint Peripheral pulmonary artery stenosis masquerading as pulmonary hypertension: a diagnostic and therapeutic challenge
    Tatyana Kushner
    Department of Internal Medicine, Mount Sinai Medical Center, New York, NY, USA
    Vasc Med 17:235-8. 2012
    ..Treatment consists of balloon angioplasty and stenting of the affected vessels, although the procedure can be complicated by reperfusion pulmonary edema...